treatment

Side effects of immunotherapy: what to look for and when?

Side effects of immunotherapy: what to look for and when?

Posted by  | treatment

Julie Brahmer, M.D., director of the Thoracic Oncology Program, began treating patients with immunotherapy drugs nearly a decade ago. She led one of the first large studies of the popular drugs, which was reported in 2012. Since then, Brahmer, a program leader in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, has become an expert in identifying(...)

Palliative medicine focus at #ASCO16 meeting

Palliative medicine focus at #ASCO16 meeting

Posted by  | treatment, Uncategorized

Tom Smith, M.D., wants cancer patients to live well. Fewer side effects, better quality of life, more joyful time with family…these are among the primary goals, he says, of palliative medicine. Researchers have studied the impact of palliative medicine programs on patients’ outcomes, and results show that patients benefit, says Smith. “A lot of aggressive(...)

New immunotherapy drug approved to treat bladder cancer

Posted by  | treatment

A new immunotherapy drug -- the first in its class -- was approved by the Food and Drug Administration last week for bladder cancer. We asked David McConkey, Ph.D., director of the Johns Hopkins Greenberg Bladder Cancer Institute, to explain the significance of this milestone: "The approval of atezolizumab is arguably the most transformative thing(...)

Chemotherapy advances pinpoint mutations for more personalized care

Posted by  | treatment

Chemotherapy is a systemic therapy, and “in the past, lung cancer treatment was really a one-size-fits-all care,” says Russell K. Hales, M.D.  “Thanks to advances in treatment, we’ve been able to transition to more personalized care.  We can assess the tumor for changes that can be targeted with customized therapy, also known as molecular profiling. (...)

Melanoma drug FDA approved

Posted by  | treatment

This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval(...)